Caris Life Sciences Launches World's First WGS/WTS Assay for Myeloid Malignancies

Key Facts

1Caris Life Sciences finalized the Achieve 1 study, validating the accuracy of its Caris Detect multi-cancer early detection test.

2Results demonstrated the superiority of Whole Genome Sequencing (WGS) over methylation-based approaches in sensitivity and specificity.

3This milestone is a key step toward the future launch of the Caris Detect™ test.

Caris Life Sciences (NASDAQ: CAI) has announced the launch of Caris ChromoSeq, the world's first Whole Genome and Whole Transcriptome Sequencing (WGS/WTS) assay for myeloid malignancies. This innovative test is specifically designed for patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). The assay also supports the evaluation of patients experiencing unexplained cytopenia that persists for more than 4 months. This commercial launch follows the company's successful Achieve 1 study, which validated the accuracy of its AI-driven diagnostic platform. By transitioning from clinical validation to commercial availability, Caris strengthens its leadership in precision medicine and molecular diagnostics. Investors are closely monitoring the commercial rollout of ChromoSeq as a key driver for the company's growth and revenue potential on the NASDAQ.

5 months ago

Version History

Version 15 months ago

What changed: The company transitioned from clinical study validation to the commercial launch of Caris ChromoSeq for myeloid malignancies and confirmed its NASDAQ ticker as CAI.